The practice of using fresh osteochondral allografts for the repair of articular cartilage lesions has evolved over the last two decades. One major change that has occurred is that grafts are now being stored for longer intervals due to concerns of potential infectious disease transmission. Currently, most osteochondral allografts are implanted after a two to four week storage period and occasionally grafts are being refrigerated for upwards of six weeks. This prolonged storage period may adversely affect the quality of the cartilage being implanted, as was shown by several studies.
MATERIALS & METHODS:
Eight human distal femurs were obtained within 96 hours of donor death and separated into 15mm diameter cores with 10mm of subchondral bone. Cores were then stored in ASM, a serum free media supplemented with antibiotics, or 10% FBS and assessed at baseline and 28 days as follows: Viability and viable cell density: Cartilage was sectioned and subjected to a live/dead staining protocol. The specimens were then examined under a confocal laser microscope. Live and dead cells were counted and percent viability was calculated using NIH Image-1.6 software. 3 Proteoglycan synthesis: Cartilage slices were placed in medium containing 5µCi/ml of 35 SO 4 and incubated at 37°C for 48 hours. The specimens were then washed, freeze-dried, weighed, and hydrolyzed. The hydrolysate was then analyzed in a liquid scintillation spectrometer for quantification of 35 SO 4 incorporation.
4
Glycosaminoglycan (GAG) content: Cartilage slices were hydrolyzed and subjected to a colorimetric assay for the determination of hexosamine as a measure of GAG content.
Statistics: The groups were analyzed using single factor analysis of variance. Results expressed as percentages were subjected to arcsin transformation prior to analysis. Significance level was prospectively set at α=0.05. Overall results are expressed as mean ± standard deviation.
RESULTS:
Chondrocyte viability and cell density were significantly lower in grafts stored in ASM compared to FBS, 27.3% versus 67.5% (p < 0.01), and 3,250 cells/mm 3 versus 8,960 cells/mm 3 respectively (p < 0.01). The metabolic activity determined by proteoglycan synthesis was significantly better in the specimens stored in FBS (p < 0.01). No significant difference was detected between the glycosaminoglycan content between the day one or day 28 grafts or between the grafts stored in ASM versus FBS. 
DISCUSSION:
The results of this study demonstrate that prolonged storage of osteochondral allografts at 4° C adversely affects the quality of grafts regardless of media choice. Nonetheless, fetal bovine serum (FBS) does appear to better preserve the graft's chondrocyte viability, viable cell density, and metabolic activity at this temperature. Additionally, the chondrocyte loss in the critically important superficial region was abated after storage in FBS. The importance of this finding cannot be understated given the importance of the superficial zone in the normal mechanics of the knee joint and the expression of lubricin, a proteoglycan secreted and accumulated in the superficial zone that is known to contribute to joint lubrication.
Although FBS outperformed the serum-free media in this study, these results need to be considered with caution because the clinical ramifications of storage in FBS are not known. In particular, the risks of infectious disease transmission or immunologic rejection have yet to be investigated.
